Drug Price Trends for SAXENDA

Average Pharmacy Cost for SAXENDA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
SAXENDA 18 MG/3 ML PEN	00169-2800-15	86.74776	ML	2025-01-22
SAXENDA 18 MG/3 ML PEN	00169-2800-15	86.73560	ML	2024-12-18
SAXENDA 18 MG/3 ML PEN	00169-2800-15	86.69077	ML	2024-11-20
SAXENDA 18 MG/3 ML PEN	00169-2800-15	86.66178	ML	2024-10-23

Market Analysis and Price Projections for SAXENDA (Liraglutide)

Introduction to SAXENDA

SAXENDA, also known as liraglutide, is an FDA-approved injectable medication used for weight loss in adults with obesity. It is part of the GLP-1 (glucagon-like peptide-1) receptor agonist class, which helps regulate appetite and increase feelings of fullness to promote weight loss[2].

Market Overview

The global anti-obesity drugs market, in which SAXENDA is a key player, is experiencing significant growth. Here are some key points:

• Current Market Size: The global market for anti-obesity drugs was estimated at $2.7 billion in 2023[4].
• Projected Growth: This market is projected to reach $4.8 billion by 2030, growing at a CAGR of 8.7% from 2023 to 2030[4].

Regional Market Analysis

The market for SAXENDA is analyzed across several key regions:

• United States: The U.S. market is a significant segment, with an estimated value of $827.9 million in 2023. It is expected to continue growing due to high demand and increasing healthcare spending[4].
• Europe: Countries like Germany, France, Italy, Spain, and the UK are part of the EU5, where the market is expected to grow, albeit at a slower pace than in the U.S. due to health technology assessments and pricing regulations[1][3].
• Japan: Japan is another key market, forecasted to grow at a CAGR of 7.9% from 2023 to 2030[4].

Competitive Landscape

SAXENDA operates in a competitive market with several other anti-obesity medications:

• SAXENDA vs. Wegovy: Both are GLP-1 receptor agonists from Novo Nordisk, but Wegovy (semaglutide) has shown more significant weight loss results in clinical trials. Wegovy requires weekly injections, whereas SAXENDA requires daily injections[2].
• Other Emerging Therapies: Drugs like tirzepatide (Mounjaro) from Eli Lilly, which is currently approved for type 2 diabetes but is expected to be approved for obesity soon, pose a competitive threat. Additionally, oral GLP-1s and dual/triple combination drugs are in the pipeline, which could further impact the market[3].

Price and Cost Analysis

The cost of SAXENDA can be substantial:

• List Price: The list price for a 30-day supply of SAXENDA is approximately $1,349.02[5].
• Average Monthly Cost: Without insurance, the average monthly cost is around $1,806[2].
• Insurance Coverage: The cost can vary significantly depending on insurance coverage. Some plans may cover SAXENDA, but it is not typically covered by Medicare Part D for weight loss[2].

Savings and Discounts

To make SAXENDA more affordable, several options are available:

• Saxenda Savings Offer: Through Novo Nordisk, eligible patients with private or commercial insurance can pay as little as $25 for a 30-day supply[5].
• Coupons and Patient Assistance Programs: Websites like SingleCare and GoodRx offer coupons and discounts. Purchasing a 3-month supply can also be more cost-effective[5].

Market Forecast

The market forecast for SAXENDA and other anti-obesity drugs is optimistic:

• Sales Projections: Branded anti-obesity drugs, including SAXENDA, are expected to reach sales of $44 billion by 2030, with Novo Nordisk's franchise and Eli Lilly's tirzepatide dominating the market[3].
• Regional Growth: The U.S. is expected to account for nearly 70% of this figure, with slower growth anticipated in Europe due to pricing regulations[3].

Regulatory and Developmental Activities

SAXENDA's market position is influenced by its regulatory and developmental activities:

• Regulatory Milestones: Detailed descriptions of SAXENDA's regulatory milestones and developmental activities are crucial for understanding its market trajectory[1].
• Patent Information: The report includes patent information with expiry timelines, which can impact future market dynamics[1].

SWOT Analysis and Analyst Views

A comprehensive SWOT analysis and analyst views provide insights into SAXENDA's market position:

• Strengths: Dominant market position, effective in weight loss, and strong backing from Novo Nordisk.
• Weaknesses: High cost, daily injection requirement, and potential side effects.
• Opportunities: Growing demand for anti-obesity drugs, potential expansion into new markets.
• Threats: Emerging competitors, regulatory challenges, and pricing pressures[1].

Impact of Emerging Therapies

The launch of late-stage emerging therapies will significantly impact the market:

• Wegovy and Mounjaro: These drugs are expected to provide tough competition to SAXENDA, especially given their more favorable dosing schedules and potentially greater weight loss outcomes[2][3].

"Unprecedented demand in obesity coupled with the strong relaunch of Wegovy, which serves as a benchmark for future launches, underpins our upgraded sales view for the market," - Michael Shah, senior industry analyst at Bloomberg Intelligence[3].

Key Takeaways

• Market Growth: The anti-obesity drugs market is projected to grow significantly, driven by increasing demand and new therapies.
• Competitive Landscape: SAXENDA faces competition from other GLP-1 receptor agonists and emerging therapies.
• Cost and Savings: The cost of SAXENDA is high, but various savings options and patient assistance programs are available.
• Regulatory and Developmental Activities: Understanding SAXENDA's regulatory milestones and developmental activities is crucial for market analysis.

FAQs

What is the average monthly cost of SAXENDA without insurance?

The average monthly cost of SAXENDA without insurance is approximately $1,806[2].

How does SAXENDA compare to Wegovy in terms of weight loss?

Wegovy yields more than double the average weight loss of SAXENDA, with a 15.8% weight loss compared to SAXENDA's 6.4%[2].

Is SAXENDA covered by insurance?

Insurance coverage for SAXENDA varies by plan, but it is not typically covered by Medicare Part D for weight loss[2].

What are some ways to reduce the cost of SAXENDA?

Ways to reduce the cost include using the Saxenda Savings Offer, purchasing a 3-month supply, and searching for coupons on websites like SingleCare and GoodRx[5].

What is the projected market size for anti-obesity drugs by 2030?

The global market for anti-obesity drugs is projected to reach $4.8 billion by 2030, growing at a CAGR of 8.7% from 2023 to 2030[4].

Sources

1. ResearchAndMarkets.com: "SAXENDA (Liraglutide), Drug Insight and Market Forecast - 2032"
2. SingleCare: "Saxenda vs. Wegovy price comparison"
3. FiercePharma: "Bloomberg predicts obesity drug sales hitting $44B by 2030"
4. GlobeNewswire: "Anti-Obesity Drugs Global Strategic Business Report 2024"
5. Ro: "How Much Does Saxenda Cost With and Without Insurance?"